152 related articles for article (PubMed ID: 31829248)
1. Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients.
Yamamoto H; Hamasaki T; Onda K; Nojiri T; Aragaki M; Horie N; Sato N; Hida Y
Trials; 2019 Dec; 20(1):715. PubMed ID: 31829248
[TBL] [Abstract][Full Text] [Related]
2. A multicenter randomized controlled trial of surgery alone or surgery with atrial natriuretic peptide in lung cancer surgery: study protocol for a randomized controlled trial.
Nojiri T; Yamamoto H; Hamasaki T; Onda K; Ohshima K; Shintani Y; Okumura M; Kangawa K;
Trials; 2017 Apr; 18(1):183. PubMed ID: 28427456
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled, phase II dose-finding study of the short acting β1-blocker, landiolol hydrochloride, in patients with suspected ischemic cardiac disease.
Jinzaki M; Hirano M; Hara K; Suzuki T; Yamashina A; Ikari Y; Iino M; Yamaguchi T; Kuribayashi S
Int J Cardiovasc Imaging; 2013 Jun; 29 Suppl 1(Suppl 1):7-20. PubMed ID: 23784548
[TBL] [Abstract][Full Text] [Related]
4. Effect of landiolol hydrochloride, an ultra-short-acting beta 1-selective blocker, on supraventricular tachycardia, atrial fibrillation and flutter after pulmonary resection.
Nakano T; Shimizu K; Kawashima O; Kamiyoshihara M; Nagashima T; Ibe T; Takeyoshi I
J Clin Pharm Ther; 2012 Aug; 37(4):431-5. PubMed ID: 22059486
[TBL] [Abstract][Full Text] [Related]
5. Randomized controlled trial of landiolol, a short-acting beta-1 adrenergic receptor blocker, illustrating changes in high-molecular weight adiponectin levels after elective percutaneous coronary intervention.
Kiyokuni M; Konishi M; Saigusa Y; Iwata K; Nakayama N; Komura N; Sugano T; Ishigami T; Ishikawa T; Yamanaka T; Tamura K; Kimura K
Heart Vessels; 2020 Nov; 35(11):1510-1517. PubMed ID: 32533314
[TBL] [Abstract][Full Text] [Related]
6. Landiolol: A Review in Tachyarrhythmias.
Syed YY
Drugs; 2018 Mar; 78(3):377-388. PubMed ID: 29470800
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of the Ultra-Short-Acting β1-Selective Blocker Landiolol in Patients With Recurrent Hemodynamically Unstable Ventricular Tachyarrhymias - Outcomes of J-Land II Study.
Ikeda T; Shiga T; Shimizu W; Kinugawa K; Sakamoto A; Nagai R; Daimon T; Oki K; Okamoto H; Yamashita T;
Circ J; 2019 Jun; 83(7):1456-1462. PubMed ID: 31118364
[TBL] [Abstract][Full Text] [Related]
8. Novel use of the ultra-short-acting intravenous β1-selective blocker landiolol for supraventricular tachyarrhythmias in patients with congestive heart failure.
Adachi T; Sato A; Baba M; Hiraya D; Hasegawa T; Kuroki K; Hoshi T; Aonuma K
Heart Vessels; 2014 Jul; 29(4):464-9. PubMed ID: 23801459
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of landiolol, an ultra-short-acting β1-selective antagonist, for treatment of sepsis-related tachyarrhythmia (J-Land 3S): a multicentre, open-label, randomised controlled trial.
Kakihana Y; Nishida O; Taniguchi T; Okajima M; Morimatsu H; Ogura H; Yamada Y; Nagano T; Morishima E; Matsuda N;
Lancet Respir Med; 2020 Sep; 8(9):863-872. PubMed ID: 32243865
[TBL] [Abstract][Full Text] [Related]
10. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials.
Sakamoto A; Hamasaki T; Kitakaze M
Adv Ther; 2014 Apr; 31(4):440-50. PubMed ID: 24756366
[TBL] [Abstract][Full Text] [Related]
11. The effectiveness and safety of landiolol hydrochloride, an ultra-short-acting β1-blocker, in postoperative patients with supraventricular tachyarrhythmias: a multicenter, randomized, double-blind, placebo-controlled study.
Taenaka N; Kikawa S
Am J Cardiovasc Drugs; 2013 Oct; 13(5):353-64. PubMed ID: 23818039
[TBL] [Abstract][Full Text] [Related]
12. Perioperative Administration of an Intravenous Beta-Blocker Landiolol Hydrochloride in Patients with Lung Cancer: A Japanese Retrospective Exploratory Clinical Study.
Sakamoto A; Yagi K; Okamura T; Harada T; Usuda J
Sci Rep; 2019 Mar; 9(1):5217. PubMed ID: 30914694
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled, phase III study of the short-acting β1-adrenergic receptor blocker landiolol hydrochloride for coronary computed tomography angiography in Japanese patients with suspected ischemic cardiac disease.
Hirano M; Yamashina A; Hara K; Ikari Y; Jinzaki M; Iino M; Yamaguchi T; Tanimoto M; Kuribayashi S;
Clin Drug Investig; 2014 Jan; 34(1):53-62. PubMed ID: 24174275
[TBL] [Abstract][Full Text] [Related]
14. Landiolol, an ultra-short-acting β₁-blocker, more effectively terminates atrial fibrillation than diltiazem after open heart surgery: prospective, multicenter, randomized, open-label study (JL-KNIGHT study).
Sakamoto A; Kitakaze M; Takamoto S; Namiki A; Kasanuki H; Hosoda S;
Circ J; 2012; 76(5):1097-101. PubMed ID: 22361918
[TBL] [Abstract][Full Text] [Related]
15. Landiolol in patients with septic shock resident in an intensive care unit (LANDI-SEP): study protocol for a randomized controlled trial.
Unger M; Morelli A; Singer M; Radermacher P; Rehberg S; Trimmel H; Joannidis M; Heinz G; Cerny V; Dostál P; Siebers C; Guarracino F; Pratesi F; Biancofiore G; Girardis M; Kadlecova P; Bouvet O; Zörer M; Grohmann-Izay B; Krejcy K; Klade C; Krumpl G
Trials; 2018 Nov; 19(1):637. PubMed ID: 30454042
[TBL] [Abstract][Full Text] [Related]
16. Landiolol infusion during general anesthesia does not prevent postoperative atrial fibrillation in patients undergoing lung resection.
Aoyama H; Otsuka Y; Aoyama Y
Gen Thorac Cardiovasc Surg; 2016 Dec; 64(12):735-741. PubMed ID: 27553581
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the Therapeutic Efficacy and Safety of Landiolol Hydrochloride for Management of Arrhythmia in Critical Settings: Review of the Literature.
Matsuishi Y; Mathis BJ; Shimojo N; Kawano S; Inoue Y
Vasc Health Risk Manag; 2020; 16():111-123. PubMed ID: 32308404
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low-dose landiolol, an ultrashort-acting β-blocker, on postoperative atrial fibrillation in patients undergoing pulmonary resection for lung cancer.
Nojiri T; Yamamoto K; Maeda H; Takeuchi Y; Funakoshi Y; Maekura R; Okumura M
Gen Thorac Cardiovasc Surg; 2011 Dec; 59(12):799-805. PubMed ID: 22173677
[TBL] [Abstract][Full Text] [Related]
19. Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy.
Niwa Y; Koike M; Iwata N; Kobayashi D; Tanaka C; Fujii T; Nakayama G; Sugimoto H; Fujiwara M; Kodera Y
Hepatogastroenterology; 2014 Sep; 61(134):1546-51. PubMed ID: 25436340
[TBL] [Abstract][Full Text] [Related]
20. Randomized study on the efficacy and safety of landiolol, an ultra-short-acting β1-adrenergic blocker, in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
Hanada K; Higuma T; Nishizaki F; Sukekawa T; Yokota T; Yamada M; Saito S; Kushibiki M; Oikawa K; Abe N; Tomita H; Osanai T; Okumura K
Circ J; 2012; 76(2):439-45. PubMed ID: 22156314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
